186 related articles for article (PubMed ID: 22578375)
1. Plasma components: properties, differences, and uses.
Benjamin RJ; McLaughlin LS
Transfusion; 2012 May; 52 Suppl 1():9S-19S. PubMed ID: 22578375
[TBL] [Abstract][Full Text] [Related]
2. Update on pathogen reduction technology for therapeutic plasma: an overview.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
[TBL] [Abstract][Full Text] [Related]
3. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
4. Clinical use of fresh-frozen plasma and cryoprecipitate in neonatal intensive care unit.
Motta M; Del Vecchio A; Radicioni M
J Matern Fetal Neonatal Med; 2011 Oct; 24 Suppl 1():129-31. PubMed ID: 21942611
[TBL] [Abstract][Full Text] [Related]
5. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma.
Smith J; Rock G
Transfusion; 2010 Apr; 50(4):926-31. PubMed ID: 20051060
[TBL] [Abstract][Full Text] [Related]
6. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.
Alvarez-Larrán A; Del Río J; Ramírez C; Albo C; Peña F; Campos A; Cid J; Muncunill J; Sastre JL; Sanz C; Pereira A
Vox Sang; 2004 May; 86(4):246-51. PubMed ID: 15144529
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.
Mintz PD; Neff A; MacKenzie M; Goodnough LT; Hillyer C; Kessler C; McCrae K; Menitove JE; Skikne BS; Damon L; Lopez-Plaza I; Rouault C; Crookston KP; Benjamin RJ; George J; Lin JS; Corash L; Conlan MG
Transfusion; 2006 Oct; 46(10):1693-704. PubMed ID: 17002625
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic plasma exchange in the treatment of the hereditary thrombotic thrombocytopenic purpura].
Cermáková Z; Korístka M; Korístková B; Hrdlicková R; Suláková T; Furková J; Kovárová P
Cas Lek Cesk; 2009; 148(10):493-6. PubMed ID: 20662412
[TBL] [Abstract][Full Text] [Related]
9. [Indications for fresh frozen plasma: evaluation of virus inactivating preparations].
Pindur G; Kiesewetter H; Seyfert UT; Wenzel E
Beitr Infusionsther; 1993; 31():74-80. PubMed ID: 7693268
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange.
McLeod BC
Best Pract Res Clin Haematol; 2006; 19(1):157-67. PubMed ID: 16377548
[TBL] [Abstract][Full Text] [Related]
11. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen.
Osselaer JC; Debry C; Goffaux M; Pineau J; Calomme G; Dubuc E; Chatelain B; Vandendaele MC; Hsu J; Rheinschmidt M; Lin L
Transfusion; 2008 Jan; 48(1):108-17. PubMed ID: 17900283
[TBL] [Abstract][Full Text] [Related]
12. Plasma and plasma derivatives in therapeutic plasmapheresis.
McLeod BC
Transfusion; 2012 May; 52 Suppl 1():38S-44S. PubMed ID: 22578370
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage.
Scott E; Puca K; Heraly J; Gottschall J; Friedman K
Transfusion; 2009 Aug; 49(8):1584-91. PubMed ID: 19413730
[TBL] [Abstract][Full Text] [Related]
14. Guideline for the use of fresh-frozen plasma. Medical Directors Advisory Committee, National Blood Transfusion Council.
S Afr Med J; 1998 Oct; 88(10):1344-7. PubMed ID: 9807194
[TBL] [Abstract][Full Text] [Related]
15. [Reasons for fresh frozen plasma transfusion in a general hospital].
Pita-Ramírez L; Cabrera Carbajal BE; Ortega Zavala C
Rev Invest Clin; 1999; 51(2):89-92. PubMed ID: 10410587
[TBL] [Abstract][Full Text] [Related]
16. Algorithmic and consultative integration of transfusion medicine and coagulation: a personalized medicine approach with reduced blood component utilization.
Brown RE; Dorion RP; Trowbridge C; Stammers AH; Fitt W; Davis J
Ann Clin Lab Sci; 2011; 41(3):211-6. PubMed ID: 22075502
[TBL] [Abstract][Full Text] [Related]
17. Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation.
Thiele T; Kellner S; Hron G; Wasner C; Nauck M; Zimmermann K; Wessel A; Warkentin TE; Greinacher A; Selleng K
Transfusion; 2012 Mar; 52(3):529-36. PubMed ID: 21880044
[TBL] [Abstract][Full Text] [Related]
18. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.
Yarranton H; Lawrie AS; Mackie IJ; Pinkoski L; Corash L; Machin SJ
Transfusion; 2005 Sep; 45(9):1453-8. PubMed ID: 16131377
[TBL] [Abstract][Full Text] [Related]
19. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura.
Scully M; Longair I; Flynn M; Berryman J; Machin SJ
Vox Sang; 2007 Aug; 93(2):154-8. PubMed ID: 17683359
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of albumin and compounded plasma for plasma exchange in acquired thrombotic thrombocytopenic purpura.
Hou R; Tian W; Qiao R; Zhang J
J Clin Apher; 2020 Jun; 35(3):154-162. PubMed ID: 32110837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
